Table 9

Test 2: Adverse Event Rates

Treatment-Emergent Diabetes

Treatment-Emergent Hyperlipidemia

New Event Rate*

(Base Case Rate)

Total Mean Cost

QALYs

ICER Cost/QALYs

New Event Rate**

(Base Case Value)

Total Mean Cost

QALYs

ICER Cost/QALYs

OLZ

4.6%

(3.3%)

$8567

0.733

Dominant

21.8%

(16.8%)

$8582

0.731

Dominant

RIS

4.1%

(3.2%)

$9095

0.719

-

21.4%

(14.0%)

$9122

0.717

-

QUE

4.3%

(3.6%)

$13628

0.708

-

21.3%

(14.1%)

$13666

0.706

-

ZIP

4.1%

(2.0%)

$11445

0.715

-

19.6%

(8.1%)

$11478

0.711

-

ARIP

4.1%

(2.0%)

$11632

0.710

-

16.7%

(3.6%)

$11678

0.707

-

*Source: Leslie and Rosenheck, 2005 [84]

**Source: Olfson et al., 2006 [70]

QALYs = quality-adjusted life years; ICER = incremental cost-effectiveness ratio; OLZ = olanzapine; RIS = risperidone; QUE = quetiapine; ZIP = ziprasidone; ARIP = aripiprazole

Further analysis showed that olanzapine remained dominant when the rates of diabetes for aripiprazole and ziprasidone were kept at the base case value and all others were increased.

Furiak et al. Cost Effectiveness and Resource Allocation 2009 7:4   doi:10.1186/1478-7547-7-4